Antisense Comes of Age as Kynamro NDA in FDA Queue
The use of antisense oligonucleotides in biotech drug development took another step forward with the FDA's acceptance of the new drug application (NDA) for Kynamro (mipomersen sodium) filed by Genzyme, a unit of Sanofi SA.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter